<DOC>
	<DOCNO>NCT00978211</DOCNO>
	<brief_summary>The investigator aim explore efficacy [ 90Y-DOTA ] -TOC [ 177LuDOTA ] -TOC therapy advance neuroendocrine cancer . Therefore , investigator assess response , survival long-term safety profile systemic [ 90Y-DOTA ] -TOC [ 177LuDOTA ] -TOC treatment metastasize neuroendocrine cancer patient . Adverse event assess accord criterion National Cancer Institute . Survival analyse perform use multiple regression model .</brief_summary>
	<brief_title>DOTA-TOC Metastasized Neuroendocrine Tumors</brief_title>
	<detailed_description>Background : Systemic treatment 90Yttrium ( 90Y ) label , tetraazacyclododecanetetraacetic acid ( DOTA ) modify somatostatin analog Tyr3-octreotide ( TOC ) introduce 1998 ( Otte et al . Lancet 1998 ) . [ 90Y-DOTA ] -TOC administer intravenously bind somatostatin receptor subtype 2 , locate surface tumor cell , exert cytotoxic effect Î²-irradiation . The treatment moderate acute hematologic nephrologic toxicity develop promising therapeutic tool tumor express target receptor ( Iten et al . Clin Cancer Res 2007 , Iten et al . Cancer 2009 ) . Study Aim : To explore efficacy [ 90Y-DOTA ] -TOC [ 177LuDOTA ] -TOC therapy advance neuroendocrine cancer . Study Hypothesis : Response DOTA-TOC correlate prolonged survival . Study Type : Clinical phase II , single-center , open-label trial Patients : 1500 patient</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>histologically confirm neuroendocrine cancer stage IVc disease definition American Joint Committee Cancer , i.e . occurrence distant metastasis visible tumor uptake pretherapeutic somatostatin receptor subtype 2 scintigraphy ( 111InOctreoscan ) concurrent antitumor treatment secondary malignancy pregnancy breastfeed incontinence severe concomitant illness include severe psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>DOTATOC</keyword>
	<keyword>somatostatin</keyword>
	<keyword>radiopeptide</keyword>
	<keyword>Yttrium</keyword>
	<keyword>Lutetium</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>cancer</keyword>
</DOC>